Ieq Capital LLC Invests $17.37 Million in Abbott Laboratories $ABT

Ieq Capital LLC bought a new position in Abbott Laboratories (NYSE:ABT - Free Report) during the second quarter, according to its most recent disclosure with the SEC. The firm bought 191,459 shares of the healthcare product maker's stock, valued at approximately $17,373,000.

Several other hedge funds have also bought and sold shares of ABT. Freemont Management S.A. boosted its holdings in Abbott Laboratories by 197.2% in the 4th quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker's stock worth $1,341,000 after buying an additional 7,100 shares during the period. Thrivent Financial for Lutherans lifted its position in shares of Abbott Laboratories by 24.3% in the fourth quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker's stock valued at $30,931,000 after acquiring an additional 48,286 shares in the last quarter. Aureus Asset Management LLC boosted its stake in shares of Abbott Laboratories by 25.0% in the first quarter. Aureus Asset Management LLC now owns 331,920 shares of the healthcare product maker's stock worth $34,078,000 after acquiring an additional 66,422 shares during the period. North Dakota State Investment Board purchased a new stake in shares of Abbott Laboratories during the fourth quarter worth about $7,439,000. Finally, Cambridge Investment Research Advisors Inc. raised its stake in Abbott Laboratories by 13.6% during the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 331,204 shares of the healthcare product maker's stock valued at $41,497,000 after purchasing an additional 39,573 shares during the period. Institutional investors own 75.18% of the company's stock.

Abbott Laboratories Price Performance

NYSE:ABT opened at $112.63 on Monday. The firm has a market capitalization of $194.89 billion, a price-to-earnings ratio of 36.45, a PEG ratio of 2.18 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The business has a 50 day simple moving average of $102.61 and a 200-day simple moving average of $100.14. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The firm had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. During the same quarter in the previous year, the company posted $1.26 EPS. The company's revenue for the quarter was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities analysts forecast that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were given a dividend of $0.63 per share. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.2%. Abbott Laboratories's payout ratio is 81.55%.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: The FDA approved Abbott’s Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients age two and older. The wearable is the first of its kind to track both glucose and ketones, strengthening Abbott’s position in diabetes care and creating potential for future integration with insulin-pump systems. FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking
• Positive Sentiment: Abbott received the European CE Mark for its next-generation Amulet 360 left atrial appendage occluder. The device is designed to reduce stroke risk in certain atrial-fibrillation patients and may reduce reliance on blood-thinning medication, supporting growth in Abbott’s structural-heart business. Abbott's next-generation Amulet 360 device receives CE Mark
• Positive Sentiment: Analyst coverage remains supportive, with TD Cowen expecting Abbott’s stock to rise. Separately, Zacks highlighted ABT as a strong long-term momentum candidate, suggesting improving price trends and investor interest despite its premium valuation. TD Cowen Analyst Says Abbott Stock Price Expected to Rise
• Neutral Sentiment: Abbott’s latest reported quarter exceeded consensus estimates, with earnings and revenue growing year over year. Management’s 2026 earnings guidance also points to continued expansion, but ABT’s elevated price-to-earnings ratio leaves the stock sensitive to execution and valuation concerns.
• Negative Sentiment: Recent coverage noted that Abbott shares fell 2.2% in the prior session even as the broader market advanced, reflecting near-term underperformance and possible profit-taking. The stock remains well below its 12-month high, so investors may want evidence that the new devices translate into meaningful sales growth. Abbott Stock Sinks as Market Gains

Analysts Set New Price Targets

Several research analysts have weighed in on the company. JPMorgan Chase & Co. upped their price target on Abbott Laboratories from $110.00 to $120.00 and gave the stock an "overweight" rating in a research note on Friday, July 17th. BTIG Research boosted their target price on shares of Abbott Laboratories from $131.00 to $134.00 and gave the stock a "buy" rating in a report on Friday, July 17th. Citigroup upped their target price on shares of Abbott Laboratories from $108.00 to $112.00 and gave the stock a "buy" rating in a research report on Friday, July 17th. TD Cowen lifted their price target on shares of Abbott Laboratories from $115.00 to $135.00 and gave the company a "buy" rating in a report on Tuesday, August 25th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $118.00 price target (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $119.50.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source